Key result
PKA activation drives HDAC4 into cardiomyocyte nuclei, raising the nucleo-to-cytoplasmic ratio by ~60%.
CaMKII and PKA compete to regulate HDAC4 nuclear localization in cardiomyocytes, a balance that is disrupted in heart failure.
Suggests kinase imbalance disrupts HDAC4 localization in failing hearts; leaves open whether modulating this axis offers therapeutic benefit.
by > 60%). These PKA-mediated effects were abolished in cells pretreated with PKA inhibitors and in cells expressing mutant HDAC4 in S265/266A mutant. In physiological conditions where both kinases are active, PKA-dependent nuclear accumulation of HDAC4 was predominant in the very early response, while CaMKII-dependent HDAC4 export prevailed upon prolonged stimuli. This orchestrated co-regulation was shifted in failing cardiomyocytes, where CaMKII-dependent effects predominated over PKA-dependent response. Importantly, human cardiomyocytes showed similar CaMKII- and PKA-dependent HDAC4 shifts. Collectively, CaMKII limits nuclear localization of HDAC4, while PKA favors HDAC4 nuclear retention and S265/266 is essential for PKA-mediated regulation. These pathways thus compete in HDAC4 nuclear localization and transcriptional regulation in cardiac signaling.
No takes yet. Share an insight, caveat, or question.
Helmstadter et al. (2021) studied Heart failure (preclinical models). CaMKII and PKA modulators (e.g., KN93, isoproterenol, forskolin) vs. Untreated/baseline cardiomyocytes was evaluated on Nucleo-to-cytoplasmic HDAC4 fluorescence ratio (FNuc/FCyto). In adult cardiomyocytes, CaMKII limits nuclear localization of HDAC4, while PKA activation by isoproterenol or forskolin drives HDAC4 into the nucleus, raising the nucleo-to-cytoplasmic ratio by over 60%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: